BlackRock, Inc. just provided an update on share ownership of Intercept Pharmaceuticals

BlackRock, Inc. just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though BlackRock, Inc. claims to own 2498408 shares. This represents 7.6% of Intercept Pharmaceuticals.

Please note that typos are common in SEC filings. Please verify the information reported above before acting on it.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Business Update - Aug. 3, 2022
Intercept Pharmaceuticals Just Filed Its Quarterly Report: 14.   Net Loss Per ... - Aug. 3, 2022
Intercept Pharmaceuticals's General Counsel just disposed of 771 shares - Aug. 3, 2022
On July - July 26, 2022
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 436 shares - July 13, 2022

Auto Refresh

Feedback